1. Guideline Update for the
Management of Intravascular
Catheter-Related Infections
Sarah Nelson, Pharm.D.
Critical Care Pharmacy Resident
October 21 & 22, 2009
2. Objectives
Identify common microorganisms associated with
intravascular catheter-related infections
Analyze treatment options for infections associated
with short-term catheters
Analyze treatment regimens for infections associated
with long-term and dialysis catheters
Recognize appropriate utilization of antibiotic lock
therapy
Summarize pathogen-specific treatment
recommendations for select microorganisms
4. Epidemiology
300 million catheters are used in the United
States each year
Functions of intravascular catheters include
Administration of fluids and medications
Administration of blood products
Administration of total parenteral nutrition
Monitor hemodynamic status
Provide hemodialysis
Mermel LA, Allon M, Bouza E, et a. Clinical practice guidelines for the diagnosis and management
of intravascular catheter-related infection: 2009 update by the IDSA. Clin Infect Disease. 2009;49:1-45
5. Epidemiology
Nosocomial CRBSI > Community-acquired CRBSI
21.6 cases of CRBSI per 1,000 hospital admissions
Estimated case fatality rate of 20.6%
ICU LOS increases by 9 to 11 days
Edgeworth, J. J Hosp Infect. 2009;10:1-8
Al-Rawajfah OM, Stetzer F, Hweitt JB. Infect Control Hosp Epidemiol. 2009;30:000
Ramritu P, Halton K, Collignon P, et al. An J Infect Control. 2008;36:104-17
6. Types of Intravascular Devices
Type Function
Peripheral venous catheter Short-term intravascular administration
Peripheral arterial catheter Monitor hemodynamics & blood gas
Short-term central venous
catheter (CVC)
Short-term intravascular administration
Pulmonary artery catheter Advanced hemodynamic monitoring
Peripherally inserted central
catheter (PICC)
Short-term intravascular administration
(alternative to a CVC)
Long-term CVC Long-term tunneled vascular access
Totally implantable device Long-term subcutaneous port/reservoir
with needle access
Mermel LA, Allon M, Bouza E, et al. Clin Infect Disease. 2009;49:1-45
8. Risk Factors for CRBSIs
Type of intravascular device
Intended use for catheter
Insertion site
Experience & education of installer
Duration of catheter placement
Characteristics of catheterized patient
Utilization of preventative strategies
Mermel LA, Allon M, Bouza E, et a. Clinical practice guidelines for the diagnosis and management
of intravascular catheter-related infection: 2009 update by the IDSA. Clin Infect Disease. 2009;49:1-45
9. Diagnosis of CRBSI
Catheter tip culture + blood culture
Sonification of catheter
Simultaneous quantitative blood cultures
Differential time to positivity (DTP)
Edgeworth, J. Intravascular catheter infections. J Hosp Infect. 2009;10:1-8
10. Common Pathogens
Percutaneous Catheters
Coagulase-negative
staphlococci (CNS)
Staphlococcus aureus
Candida species
Enteric gram-negative
bacilli
Surgically Implanted &
Peripheral Catheters
CNS
Enteric gram-negative
bacilli
Staphlococcus aureus
Pseudomonas aeurginosa
Mermel LA, Allon M, Bouza E, et a. Clinical practice guidelines for the diagnosis and management
of intravascular catheter-related infection: 2009 update by the IDSA. Clin Infect Disease. 2009;49:1-45
11. Lorente et al
Design: prospective cohort
Patient population: Medical/Surgical ICU pts
with either a CVC or arterial catheter
Outcome: assess proportion of CRBSI due to
gram – rods and yeast according to catheter
site
Lorente L, Jimenez A, Santana M et al. Microorganisms responsible for intravascular catheter
related bloodstream infection according to catheter site. Crit Care Med. 2007;35:2424-27
12. Lorente et al.
Lorente L, Jimenez A, Santana M et al. Microorganisms responsible for intravascular catheter
related bloodstream infection according to catheter site. Crit Care Med. 2007;35:2424-27
Femoral site n=36 Other site n=52
Gm + bacteria 16 47
CNS 8 29
MRSA 2 7
E. faecalis 4 2
Other 2 9
Gram – bacteria 14 4
E. coli 10 1
P. aeurginosa 1 2
Candida albicans 6 1
14. Empiric Antibiotic Selection
Are antibiotics indicated?
Signs/symptoms of infection
Patient characteristics
Where is the catheter located?
Can/should the catheter be removed?
15. Catheter Removal
Short-term CVC
Not necessary unless: pt is severely ill, no other
sources of fever identified, pt has secondary
infections
Long-term CVC/Port
Not necessary unless complicated infection is
apparent (tunnel infection, port abscess,
secondary infections present)
Mermel LA, Allon M, Bouza E, et a. Clinical practice guidelines for the diagnosis and management
of intravascular catheter-related infection: 2009 update by the IDSA. Clin Infect Disease. 2009;49:1-45
Rijnders BJ, Peetermans WE, Verwaest C et al. Watchful waiting vs. immediate catheter removal in ICU patients with
suspected CRI: a randomized trial. Inten Care Med. 2004;30:1073-80
16. Empiric Antibiotic Therapy
Gram + pathogen:
Vancomycin is recommended
Daptomycin if MRSA MIC consistently > 2 mcg/mL
Gram – pathogen:
Not always necessary
Choice based off antibiogram and severity of
illness
Single agent vs. double coverage of P. aeurginosa
Double coverage should be used if pt is neutropenic, severely ill
with sepsis, or colonized with P. aeurginosa
Mermel LA, Allon M, Bouza E, et a. Clinical practice guidelines for the diagnosis and management
of intravascular catheter-related infection: 2009 update by the IDSA. Clin Infect Disease. 2009;49:1-45
17. Empiric Antifungals
Not necessary unless patient is septic AND
has any of the following:
TPN
Prolonged use of broad-spectrum antibiotics
Malignancy
Transplant recipient
Femoral catheter in place
Multi-site Candida colonizaton
Mermel LA, Allon M, Bouza E, et a. Clinical practice guidelines for the diagnosis and management
of intravascular catheter-related infection: 2009 update by the IDSA. Clin Infect Disease. 2009;49:1-45
18. Tailored Antibiotic Therapy
Detailed summary of preferred antibiotics
listed in guidelines
Local antibiogram helps dictate tailored
therapy
Duration of therapy dictated by site of
infection and pathogen isolated
Day 1 of treatment is the first day on which a
negative blood culture is obtained
Mermel LA, Allon M, Bouza E, et a. Clinical practice guidelines for the diagnosis and management
of intravascular catheter-related infection: 2009 update by the IDSA. Clin Infect Disease. 2009;49:1-45
20. Patient with a short term CVC or arterial
line with acute febrile illness
Mild or moderately ill (no
hypotension or organ failure)
Seriously ill (hypotension,
hypoperfusion, s/sx organ dysfunction)
Consider
antimicrobial
therapy
Blood cultures (2
sets, 1 peripheral)
If no other
source of fever,
remove CVC or
AC and culture
tip, replace or
exchange CVC
Blood cultures (2
sets, 1 peripheral),
remove CVC or AC
and culture tip,
replace or
exchange CVC
Initiate
appropriate
antimicrobial
therapy
Blood culture (-) &
catheter not cultured
Blood culture (-) &
catheter culture (-)
Blood culture (-) &
catheter culture ≥15 CFU
Blood culture (+) &
catheter culture ≥15 CFU
Continued fever & no
other source found,
remove & culture
CVC or AC
Look for other
source of infection
See figure 2For S. aureus, treat for 5-7 days. For
all other microbes, monitor for s/sx
infection and send repeat blood
cultures appropriately
21. Short-term CVC or AC-related bloodstream infection
Complicated Uncomplicated (infection and fever
resolved within 72 hours, no
hardware, evidence of endocarditis or
suppurative thrombophlebitis, & if S.
aureus, no active malignancy or
immunosuppression)
Suppurative
thrombophlebit
is, endocarditis,
osteomyelitis,
etc
S. aureus Enterococcus Gram - bacilli Candida spCNS
Remove
catheter &
treat 4-6
weeks, 6-8
weeks for
osteomyleitis
Remove
catheter
and treat
with
systemic
Abx for 5-7
days
If catheter
is retained,
add ALT for
10-14 days
Remove
catheter
and treat
with
systemic
Abx for ≥
14 days
Remove
catheter
and treat
with
systemic
Abx for 7-
14 days
Remove
catheter
and treat
with
systemic
Abx for 7-
14 days
Remove
catheter
and treat
with
systemic
Abx for ≥
14 days
after 1st
negative
culture
22. Long-term CVC or port-related bacteremia or fungemia
UncomplicatedComplicated
Tunnel
infection/
port
abscess
Suppurative
thrombophlebitis,
endocarditis,
osteomyelitis
S. aureus Enterococcus Gram - bacilli Candida spCNS
Remove
CVC/P
and treat
with
systemic
Abx for 7-
10 days
Remove
CVC/P and
treat with
systemic Abx
for 4-6 weeks,
6-8 weeks for
osteomyelitis
Retain
CVC/P and
treat with
systemic
Abx + ALT
for 10-14
days
Remove
CVC/P and
treat with
systemic Abx
for 4-6 weeks
Retain
CVC/P and
treat with
systemic
Abx + ALT
for 7-14
days
Remove
catheter
and treat
with
systemic
Abx for ≥
14 days
after 1st
negative
culture
Remove and
treat with
systemic
Abx 7-14
days
OR
Retain and
treat with
systemic +
ALT for 10-
14 days
Remove CVC/P if there is clinical deterioration,
persisting bacteremia or signs of complicated infection
23. Tunneled HD catheter with suspected CRBSI
Empiric Abx + ALT
Negative blood cultures Persistent bacteremia/fungemia
and fever
Resolution of bacteremia/fungemia and
fever in 2-3 days
Stop Antibiotics CNS Gram - bacilli S. aureus C. albicans Remove CVC
and administer
antibiotics
Antibiotic tx for 10-
14 days, retain CVC
and continue ALT OR
replace CVC
Remove CVC &
treat with
systemic Abx for
3 weeks if TEE-
Replace catheter
and treat with
systemic Abx for ≥
14 days after 1st
negative culture
Systemic Abx
4-6 weeks and
look for signs
of complicated
infection
Persistent bacteremia/fungemia
and fever
Remove CVC
and administer
antibiotics
Systemic Abx
4-6 weeks and
look for signs
of complicated
infection
25. Changes to the 2009 Guidelines
Short-term CVC
Addition of arterial line infection
Alteration of treatment duration
Inclusion of antibiotic lock therapy
Inclusion of specific therapy for Enterococcus sp.
Long-term CVC
Distinguishes hemodialysis catheter infection vs. long-
term CVC and port infection
Alteration of treatment duration
Inclusion of antibiotic lock therapy
Inclusion of specific therapy for Enterococcus sp.
Mermel LA, Allon M, Bouza E, et a. Clinical practice guidelines for the diagnosis and management
of intravascular catheter-related infection: 2009 update by the IDSA. Clin Infect Disease. 2009;49:1-45
26. Coagulase-negative staphylococcus
Most common contaminant AND cause of
CRBSI
Benign clinical course
Rarely leads to sepsis
Little evidence to drive treatment
recommendations
Remove catheter & DO NOT treat
Treat systemically and/or ABL
Mermel LA, Allon M, Bouza E, et a. Clinical practice guidelines for the diagnosis and management
of intravascular catheter-related infection: 2009 update by the IDSA. Clin Infect Disease. 2009;49:1-45
27. S. aureus
Important to determine uncomplicated from
complicated infection to determine treatment
duration
Infective endocarditis commonly associated with S.
aureus bacteremia
TEE should be completed 5-7 days after onset of bacteremia
Risk factors associated with complicated S. aureus
bacteremia:
+ blood cultures >72 hours after initiation of Abx
Community-acquired infection
Skin changes consistent with septic emboli
Mermel LA, Allon M, Bouza E, et a. Clinical practice guidelines for the diagnosis and management
of intravascular catheter-related infection: 2009 update by the IDSA. Clin Infect Disease. 2009;49:1-45
28. S. aureus
Wilcox et al
Design: randomized, double-blind, non-inferiority
Intervention:
Vancomyin (weight-based dosing)
Linezolid 600 mg every 12 hours
Endpoint: Microbiological and clinical cure
Outcome:
Microbiological cure:
86% for vancomycin vs. 81% for linezolid
Clinical cure:
76% for vancomcyin vs. 79% for linezolid
Wilcox MH, Tack KJ, Bouza E et al. Complicated skin and skin-structure infections and catheter-related bloodstream
infections: non-inferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48:203-12
29. Enterococcus sp.
New addition to the guidelines
Account for 10% of all nosocomial
bloodstream infections
60% of E. faecalis was resistant to vancomycin
No good data to support
Role of combination therapy
Duration of treatment
Jones Rn, Marshall SA, Pfaller MA et al. Nosocomial enterococcal blood stream infections in the SCOPE program.
Diagn Microbiol Infect Dis. 2004;39:309-17
30. Gram - bacilli
Rate of gram – bacilli associated CRBSI is
decreasing
Resistance to gram – bacilli increasing
Role of double antibiotic coverage for CRBSI
Wilcox MH, Tack KJ, Bouza E et al. Complicated skin and skin-structure infections and catheter-related bloodstream
infections: non-inferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48:203-12
31. Gram - bacilli
Safdar N et al.
Design: meta-analysis
Outcome: mortality in monotherapy vs.
combination therapy in gram – bacteremia
Results:
Combination therapy for P. aeurginosa demonstrated
a significant mortality benefit (OR 0.5, 95% CI 0.3-0.79)
Mortality not reduced with utilization of combination
therapy for other gram - bacilli
Safdar N, Handelsman J, Maki D. Does combination antimicrobial therapy reduce mortality in gram-negative bacteremia?
Lancet Infect Dis. 2004;4:519-27
33. Antibiotic Lock Therapy (ALT)
Attempt to salvage current intravascular
catheter
Small amount of antibiotic is retained in the
catheter lumen to eradicate colonized
microorganisms
Used in combination with systemic antibiotics
for 7-14 days
Segara-Newnham M, Martin-Cooper EM. Antibiotic Lock Technique: a review of the literature.
Annals of Pharmacotherapy. 2005;39:311-8
34. Advantages of ALT
Negligible risk of adverse effects
Increased local concentration of antibiotic
Ease of administration
Ability to administer in an outpatient setting
Decreases need for catheter replacement
Cost-saving measure
Segara-Newnham M, Martin-Cooper EM. Antibiotic Lock Technique: a review of the literature.
Annals of Pharmacotherapy. 2005;39:311-8
35. Types of ALT
Antibiotics
Cefazolin, 5mg/mL
Vancomycin, 5mg/mL
Ampicillin, 10 mg/mL
Ceftazidime, 0.5 mg/mL
Ciprofloxacin, 0.2 mg/mL
Gentamicin, 1 mg/mL
Ethanol 70%
Mermel LA, Allon M, Bouza E, et a. Clinical practice guidelines for the diagnosis and management
of intravascular catheter-related infection: 2009 update by the IDSA. Clin Infect Disease. 2009;49:1-45
36. Fernandez-Hidalgo et al.
Design: retrospective/prospective
Intervention
Gram + organism: vancomycin 2 mg/mL
Gram - organism: ciprofloxacin 2mg/mL OR amikacin 2
mg/mL
Treatment duration: 10-14 days
Outcomes
Cure: negative cultures at 1 month
Treatment failure: positive cultures or presence of fever
>72 hours after start of ALT or expansion of infection
Relapse: new episode of infection with same
microorganism within 30 days of treatment completion
Fernandez-Hidalgo N, Almirante B, Calleja R, et al. Antibiotic lock therapy for long-term intravascular catheter-related
bacteremia: results of an open, non-comparative study. J Antimicro Chemotherapy. 2006:57:1172-80
37. Fernandez-Hidalgo et al.
Organism No. of isolates
Gram + organisms 80
CNS 56
S. aureus 20
E. faecalis 2
other 3
Gram – organisms 26
E. coli 11
P. aeurginosa 5
other 10
Polymicrobial infection 8
Fernandez-Hidalgo N, Almirante B, Calleja R, et al. Antibiotic lock therapy for long-term intravascular catheter-related
bacteremia: results of an open, non-comparative study. J Antimicro Chemotherapy. 2006:57:1172-80
38. Fernandez-Hidalgo et al.
Treatment success occurred in 93 cases (82%)
Gram + infection cure rate: 78%
Gram - infection cure rate: 92%
By treatment day 7, all cultures were negative
Unsuccessful outcomes occurred in 21 cases
Treatment failure: 13 cases
Relapses: 7 cases
Death: 1 case
Mean catheter salvage duration: 163 days
Fernandez-Hidalgo N, Almirante B, Calleja R, et al. Antibiotic lock therapy for long-term intravascular catheter-related
bacteremia: results of an open, non-comparative study. J Antimicro Chemotherapy. 2006:57:1172-80
39. Fortun et al.
Design: prospective, randomized
Intervention
Systemic therapy alone
Systemic therapy + ALT
Gram + organism: vancomycin 2 mg/mL
Gram - organism: ciprofloxacin 2mg/mL OR gentamicin 2 mg/mL
Treatment duration: 14 days
Outcomes
Cure: negative cultures 2-5 days after completion of
treatment and no colonization present
Treatment failure: catheter removal, persistence of
colonization, relapse of bacteremia
Fortun J, Grill F, Martin-Davis, P. et al. Treatment of long-term intravascular catheter-related bacteremia with
antibiotic lock therapy. J Antimricob Chemotherapy. 2006;58:816-821
40. Fortun et al.
Organism ALT + systemic
therapy
N=19
Systemic therapy only
N=29
CNS 14 19
S. aureus 3 4
Gram -
bacteria
2 6
Fortun J, Grill F, Martin-Davis, P. et al. Treatment of long-term intravascular catheter-related bacteremia with
antibiotic lock therapy. J Antimricob Chemotherapy. 2006;58:816-821
41. Fortun et al.
Fortun J, Grill F, Martin-Davis, P. et al. Treatment of long-term intravascular catheter-related bacteremia with
antibiotic lock therapy. J Antimricob Chemotherapy. 2006;58:816-821
42. Ethanol Locks
Antiseptic agent, bactericidal
Active against gram + and gram – organisms
and fungi
Non-toxic in doses administered
Advantageous in patients with multi-drug
resistant pathogens
May be best option for PREVENTION of CRBSI
and catheter colonization
Broom J, Woods M, Allworth A. Ethanol lock therapy to treat tunnelled central venous catheter associated blood
stream infections: results from a prospective trial. Scandinavian Journal of Infect Disesase. 2008;40:399-406
44. Preventative Strategies
Hand hygiene
Sterile precautions during insertion
Skin antisepsis (chlorhexidine, iodine)
Daily inspection and documentation of exit site
Avoidance of femoral site utilization
Removal of device as soon as it is no longer
required
Utilization of antimicrobial impregnated catheters
Edgeworth, J. Intravascular catheter infections. J Hosp Infect. 2009;10:1-8
45. Antimicrobial Impregnated CVCs
Coating of catheters with antimicrobial compounds
External coating with chlorhexidine and silver sulfadiazine
(CH-SS)
Silver, platinum, or carbon coating
Antimicrobial coatings
minocycline + rifampin (MR)
vancomycin
cefazolin
Only externally coated CH-SS and MR coated
catheters reduced the risk of CRBSI as compared to
uncoated catheters
Ramritu P, Halton K, Collignon P, et al. A systematic review comparing the relative effectiveness
of antimicrobial-coated catheters in intensive care units. An J Infect Control. 2008;36:104-17
46. Take Home Points
CRBSI are common and can happen with a variety of
intravascular devices
CNS is the predominant pathogen causing CRBSI
Pt characteristics may predispose them to other pathogens
Catheter removal is not always necessary
‘Watch and wait’ method or antibiotic lock therapy may help avoid
catheter replacement
Antibiotic lock therapy plays a larger role in current guidelines
Guidelines demonstrate proper treatment for short-term,
long-term, tunneled, and port infections
Prevention of CRBSI should not be forgotten
Good afternoon. My name is Sarah Nelson. I am currently completing my critical care residency here at VCU.
Today we are going to discuss the management of catheter related bloodstream infections. The guidelines, previously published in 2001, have recently been updated by the infectious disease society of America. We will spend the next 45 or so minutes on select areas of the guidelines, spending some time orienting ourselves to the devices themselves, the pathogens that are likely to be encountered, empiric antibiotic selection, and major updates, including treatment of hemodialysis catheters and antibiotic lock therapy as well as preventative strategies. We will end with a patient case to demonstrate our knowledge and understanding of the new guidelines.
The objectives of this presentation are to:
Identify common microorganisms associated with intravascular catheter-related infections
Analyze treatment options for infections associated with short-term catheters
Devise treatment regimens for infections associated with long-term and dialysis catheters
Recognize appropriate utilization of antibiotic lock therapy
To help orient ourselves with some background to better help us understand the guidelines.
300 million catheters are used yearly, of which 3 million are central venous catheters
Venous catheters are primarily used for administration of fluids, medications, TPN, renal replacement therapies, and blood products. Arterial catheters are predominantly used for hemodynamic monitoring and collection of blood samples.
Understanding catheter function and risks common to most ICU patients helps us understand why CRBSI are very common.
A cross sectional study conducted by Omar Al-Raqajfah and colleagues used the US nationwide inpatient sample for the year 2003 to estimate the incidence and case-fatality rate associated with nosocomial BSI in the total US population. The sample set is a compilation of all inpatient community hospital stays from 994 hospitals in 37 states Cases were identified by ICD-9 code with the assumption that each patient could only have 1 CRBSI per admission. They found 185,824 patients with at least 1 code for BSI in the primary or secondary ICD-9 code fields. Of these patients, approximately 72,000 (39%) had community acquired BSI where the rest had acquired them on a hospital stay.
Patients with nosocomial BSI had on average more procedures and comorbidities. Only 7% of the nosocomial infections were polymicrobial The most common pathogen was staph aureus in the nosocomial acquired BSI, whereas e. coli was the most common pathogen in patients with a documented community acquired BSI
21.6 cases of CRBSI per 1,000 hospital admissions
Estimated case fatality rate of 20.6%
Also, the rate of CRBSI in ICU patients rather than general floor patients as they have a greater likelihood of having and using a catheter for an extended duration of time, have more frequent manipulation of the catheter, have a higher likelihood of emergent catheter insertion such that aseptic technique is compromised, gerater underlying illness and more immunosuppression. This increases their LOS in an ICU.
In this study, risk factors for nosocomial BSI were mechanical ventilation, CVC placement, TPN, peripheral or arterial line placement, other infections, or malnutrition
This chart reviews various types of intravascular catheters that may be encountered in our patients.
Peripheral Venous Access
This is the typical "hospital IV" line put in your hand or forearm when you are admitted to the hospital. It is a short catheter, usually 3/4 to 1 inch long, inserted into a small peripheral vein and designed to be temporary
An arterial line, or art-line, is a thin catheter inserted into an artery. It is most commonly used in intensive care medicine to monitor the blood pressure real-time (rather than by intermittent measurement), and to obtain samples for arterial blood gas measurements. It is not generally used to administer medication.
An arterial line is usually inserted in the wrist (radial artery); but can also be inserted into the elbow (brachial artery), groin (femoral artery), foot (dorsalis pedis artery).
Central venous catheter
Pulmonary artery catheter
Peripherally Inserted Central Catheters
These catheters are centrally placed, meaning the tip ends up in the Superior Vena Cava. "Peripherally inserted" means it goes into your body near your elbow, in the brachial vein, and the tip is threaded up into your SVC. Two brand names for this type of catheter are Groshong and Intrasil
Tunneled Central Catheters (long term central catheter)
These catheter tips also end up in the Superior Vena Cava, but the other end is tunnelled about six inches away under the skin on the chest. On the catheter, inside this skin tunnel, is a Dacron cuff which your skin seals around, preventing bacteria from crawling along the outside of the catheter into the bloodstream. Two popular brand names of this type of catheter are Hickman and Groshong.
Implanted Ports
Implanted ports have all of the advantages of a central line except they are not always immediately available for use. A port is a small titanium reservoir with a rubber "stopper" that is attached to the catheter entering your vein below the collarbone. The whole thing is implanted under the skin in an outpatient procedure with local anesthesia and IV sedation.
These are examples of central venous catheters. You can tell the are inserted centrally rather than peripherally as the portion which extends into the vein is not long. 3 catheters are shown here, a double lumen, single lumen and triple lumen catheter progressing from right to left across the screen. In a critical care setting, double and triple lumen catheters predominate as patients normally require multiple medications at the same time. Also, TPN requires a dedicated line. In the right hand corner is a device used to place a catheter. The same device can be used to replace a CVC if a CRBSI is suspected and there are no other sites available for placement of a new CVC.
It is important to know who is at risk for acquiring a catheter related infection. The following is a short list of factors that have been associated with CRBSI.
There are several ways to diagnosis a CRBSI. The first 2 methods listed require the removal of the catheter where as the second two methods do not. The latter methods are relatively new in the diagnosis of CRBSI but have good sensitivity and specificity for diagnosis while allowing the catheter to be retained if it is determined not to be the source of bacteremia.
Catheter tip + blood culture: The catheter tip is rolled along an agar plate for colonization and a peripheral blood is obtained and plated for growth. If the same organism is isolated from both growth medias, and the quantity of organisms is >15 colonies from the catheter tip, a CRBSI can be diagnosed. This method is quick and cheap and has sensitivity and specificity of 85% and 82% respectively.
Sonification of a catheter involved immersing the removed catheter in broth, applying sonification to release microorganisms held inside the catheter, and plating and quantifing catheter microorganism load. If >10^3 microorganisms are obtained, and correlate with a peripheral blood culture, a diagnosis can be made. Sensitivity and specificity of this method is 83% and 87% respectively
Simultaneous quantitative blood culture diagnosis requires 2 blood culture be drawn, 1 through the catheter under suspect, the other via peripheral stick. If both cultures grow the same bacteria and the catheter culture has a five fold greater colony count than the peripheral blood culture, a diagnosis can be made. This technique has a 75% specificity and 97% sensitivity for short term catheters
DTP is similar to the simultaneous blood culture method, however a diagnosis is made when the culture from the catheter grows bacteria 2 hours before the peripheral blood culture grows the same bacteria. This method as a sensitivity of 89% and specificity of 87% for short term catheters.
So which organisms are we likely to see when diagnosing or identifying a CRBSI? It depends on the type and site of catheter. Coagulase-negative staphylococcus is the most common pathogen identified in all types of CRBSI.
Lorente and colleagues had identified that, in previous studies, microorganisms which normally cause CRBSI have been clearly identified, however the rate at which each microorganism is likely to cause an infection at certain sites is not clearly identified. They set out to identify which patients are at higher risk for CRBSI due to GNR or yeast, which would perhaps alter their empiric antibiotics
Pts were an average of 57 years of age, admitted for a cardiac surgery procedure, average apache II score of 17, with their catheter in place for 7 days prior to infection and ICU stay close to 2 weeks prior to infection
Patients with a CRBSI originating from a femoral line experienced infection due to GNR or yeast significantly more than those with catheters inserted at other sites (mostly jugular and subclavian veins, 5 art lines).
Empiric and tailored antibiotic therapy is important in the treatment of CRBSI. Empiric therapy should be chosen based on patient characteristics, but should always include vancomycin for gram + coverage (CNS, MRSA) in an ICU setting when the patient meets qualifications for likely having a nosocomial bloodstream infection.
This is illustrated by a study completed by Ibrahim and colleagues who looked at 492 medical or surgical ICU patients being treated for a bloodstream infection. Of the 492 patients, 147, or 30%, received inappropriate antibiotic therapy. This translated into a mortality rate of 62%. This is compared to a mortality rate 28% for those treated correctly. Pathogens most likely to be mistreated include VRE, MRSA, candida, CNS, and pseudomonas aeurginosa.
The selection of appropriate antibiotics is extremely important. As indicated by a study published in CHEST in 2000 looking at patients in a medical and surgical intensive care units, 61.9%, of patients whom received inappropriate antibiotics died whereas only 28.4% of those who received appropriate antibiotics, a difference which was statistically significant.
The up to 91% of short term CVCs are removed for suspected CRBSI unnecessarily.
Secondary infections: endocarditis, suppurative thrombophlebitis, osteomyleitis
A study published in Intensive care medicine assessed whether ‘watchful waiting’ vs immediate removal and replacement of suspected infected catheter (ie. Source of unknown infection). Patients could not be neutropenic, have a documented bloodstream infection, have erythema, induration or purulence at the insertion site, or be hemodynamically unstable. They were randomized to 2 groups, the standard of care group, in which the catheter was immediately removed, or the investigational group, where the catheter was not removed unless blood cultures can back positive or the patient has persistent sepsis. 64 patients were included in the study. They found a 62% reduction in CVC removal when using the watchful waiting method and resolution of fever, duration of ICU stay and mortality did not differ between groups.
Empiric antibiotic therapy is defined and suggested in the guidelines. It recommends . . .
In the back of your handout there are enlarged flowcharts which are pulled from the guidelines. The changes to the guidelines are indicated with an arrow.
Kaplan meier survival curves for the intention to treat population found no statistically significant difference between the 2 treatment groups among patients with s. aureus bacteremia. In fact, in patients were less likely to survive if treated with linezolid without documented bacteremia at baseline.
The most common route of bacterial contaminatin in a long term catheter is through the hub, which supports the use of ALT.
Fills the lumen of the catheter with antibiotic at concentrations 100-1000 fold higher than usual target concentrations and allowing it to dwell (lock) for a period of time while the catheter is not in order to sterilize it.
Fernandex-Hidalgo and colleagues from Spain completed the largest published study looking at the effectiveness of ALT in CRBSI associated with long-term CVCs. They completed a retrospective study from 1996-2003, then transitioning to a propective study, mandating antibiotic selection and duration.
Patients were excluded if they had a pocket, tunnel, or exit-site infection, had complications of CRBSI such as endocarditis or septic thrombophlebitis, candidemia, or hemodynamic instability at the time of diagnosis.
CRBSI was defined as 2 positive cultures, with catheter culture growing 5-fold more CFU than the peripheral blood culture in the presence of signs/symptoms of infection
They included 98 patients in their review. Most patients had access for the administration of chemotherapy, dialysis, or TPN and had tunneled catheters located in the jugular vein.
On average, patients were treated with 12 days of systemic therapy and ALT.
Treatment failure was often associated with gram + infection, with 8 pts having s. aureus, 4 CNS, 1 p. aeurginosa
Fortun and colleagues further looked at the outcome when ALT was used with systemic therapy versus systemic therapy alone. Interventions and outcomes are similar to the previous study, with the exception of the use of gentamicin rather than amikacin, treating for 14 days total, and less stringent requirements for a successful outcome.
They looked at a total of 48 patients. 19 whom received systemic plus ALT therapy and 29 who received systemic therapy alone. Patients were in their late 50s, required a long-term CVC for chemotherapy or administration of TPN
Successful treatment was observed in 84% of episodes in the ALT group compared with 65% of episodes in the control group (P = 0.27). Specific analysis of CoNS episodes demonstrated that ALT cured 93% of them versus 79% in the control group (P = 0.36)
The overall mortality was 16% and 24% in the study group and the control group, respectively. The attributable mortality was 5% in the ALT group (one patient with CoNS bacteraemia) and 7% in the control group